Trial Profile
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Ucenprubart (Primary) ; Ucenprubart (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 05 Oct 2021 Status changed from active, no longer recruiting to completed.
- 26 Jul 2021 Planned End Date changed from 30 Aug 2021 to 8 Sep 2021.
- 26 Jul 2021 Planned primary completion date changed from 3 Jun 2021 to 8 Sep 2021.